Global Health Partnership Announces First-, Second-Line AIDS Drugs Price Reductions in Developing World
May 18, 2011
The Clinton Health Access Initiative, UNITAID, and the U.K.'s Department for International Development (DFID) "said on Tuesday [they] had secured price reductions on key AIDS drugs for HIV-positive patients in poorer countries," Reuters reports. "The price of a first line regimen based on the drug tenofovir would now be less than $159 per patient per year, the partnership said -- a reduction of 60 percent from the average price paid in 2008. And a World Health Organization-recommended second-line regimen -- needed when patients develop resistance to initial treatment -- is now available at less than $410 per year, down sharply from 2008 when poorer countries paid between $800 and $1,200 per patient a year for second-line treatment," the news service reports (Kelland, 4/17).
According to a joint press release, "[t]hese price reductions were made possible through complementary efforts to build demand for new products, which stimulated market competition and led to volume-based discounts, while partnering with suppliers to achieve cost reductions through more efficient manufacturing processes and sourcing of raw materials" (5/17).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)